Riluzole

DEA Class;  Rx

Common Brand Names; Rilutek, Tiglutik, Exservan

Hypersensitivity to drug or any component of the formulation

• Oral hypoesthesia (29%)
• Asthenia (19%)
• Nausea (16%)
• Decreased lung function (10%)
• Hypertension (5%)
• Abdominal pain (5%)
• Vomiting (4%)
• Arthralgia (4%)
• Dizziness (4%)
• Dry mouth (4%)
• Insomnia (4%)
• Pruritus (4%)
• Tachycardia (3%)
• Flatulence (3%)
• Increased cough (3%)
• Peripheral edema (3%)
• Urinary tract infection (3%)
• Circumoral paresthesia (2%)
• Somnolence (2%)
• Vertigo (2%)
• Eczema (2%)
• Acute hepatitis
• Icteric toxic hepatitis
• Renal tubular impairment
• Pancreatitis

Cases of severe neutropenia (absolute neutrophil count <500/mm³) within first 2 months of treatment reported; advise patients to report febrile illnesses

Interstitial lung disease, including hypersensitivity pneumonitis, reported in patients receiving therapy; discontinue immediately if interstitial lung disease develops

There are no studies in pregnant women, and case reports have been inadequate to inform of drug-associated risk

Unknown if risk of major birth defects and miscarriage in patients with amyotrophic lateral sclerosis

Unknown if distributed in human breast milk